Related Experiment Videos
Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines
W T Couldwell1, D R Hinton, S He
1Department of Neurological Surgery, University of Southern California School of Medicine, Los Angeles 90033.
Abstract:
Previous work has demonstrated the importance of the protein kinase C (PKC) system in regulating glioma growth, and has led to clinical trials utilizing PKC inhibitors as adjuncts in the therapy of patients harboring malignant gliomas. This study was performed to explore the possibility that inhibition of PKC in gliomas was triggering an apoptosis signal. Glioma cell lines were treated with PKC inhibitors staurosporine (10 nM), and tamoxifen (10 microM). DNA from cells treated with each of these drugs exhibited a 'ladder' pattern of oligonucleosome-sized fragments characteristic of apoptosis, thus suggesting that in glioma cells, these drugs may be cytocidal in action.
Insights
Protein kinase C (PKC) inhibitors trigger apoptosis, programmed cell death, in glioma cells. This finding suggests these drugs may be effective cytocidal agents for treating malignant gliomas.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The protein kinase C (PKC) system plays a crucial role in regulating glioma cell growth.
- PKC inhibitors have been investigated in clinical trials for malignant glioma therapy.
Purpose of the Study:
- To investigate if inhibiting PKC in gliomas induces an apoptosis signal.
- To explore the cytocidal effects of PKC inhibitors on glioma cells.
Main Methods:
- Glioma cell lines were treated with specific PKC inhibitors: staurosporine and tamoxifen.
- DNA fragmentation analysis was performed to detect apoptosis markers.
Main Results:
- Treatment with staurosporine and tamoxifen induced DNA fragmentation in glioma cells.
- The observed DNA fragmentation pattern was characteristic of oligonucleosome-sized fragments, indicative of apoptosis.
Conclusions:
- PKC inhibition triggers an apoptosis signaling pathway in glioma cells.
- The studied PKC inhibitors demonstrate cytocidal activity against glioma cells, supporting their therapeutic potential.